Category Archives: Biotech
By Julian Upton | Published: March 27, 2014
Europe’s biotech industry body, EuropaBio, has launched a report urging European governments to remain committed to biotech research, development and innovation (RDI) incentives, following release of the European Commission’s (EC) 2014 Innovation Scoreboard.
By Ben Comer | Published: March 26, 2014
Allergy season’s dank fecundity might be welcomed in many parts of America this year. Anything that’s warmer. But the worst allergy sufferers might soon be headed back to the doctor’s office for another round of allergy shots. Or perhaps not. ALK-Abelló, a Denmark-based specialty pharmaceuticals company focused solely on allergy immunotherapy products, expects FDA to […]
By Pharm Exec | Published: March 21, 2014
European physicians have insufficient knowledge of biosimilars, according to a survey carried out by the Alliance for Safe Biologic Medicines (ASBM). Only 22% of physicians consider themselves “very familiar” with this category of medicines, and while a majority (54%) have a “basic understanding” of biosimilars, 24% of participants could not define or have not heard about […]
By Jill Wechsler | Published: March 7, 2014
Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.
By Pharm Exec | Published: February 28, 2014
While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.